Galapagos Reports Nine Months 2025 Financial Results and Provides Business Update Strategic review process concluded with intention to wind down cell therapy business, representing optimal capital allocation pathway to support a stronger and sustainable future for GalapagosContinued evolution of leadership team aligned with strategic directionRobust balance sheet with €3.05 billion in cash and financial investments as of September 30, 2025; year-end 2025 cash position expected at €2.975 billion to €3.025 billion Management to host a tomorrow, November 6, 2025, at 14:00 CET / 08:00 AM ET ...
Galapagos rapporteert financiële resultaten over de eerste negen maanden van 2025 en geeft bedrijfsupdate Strategisch evaluatieproces afgerond met de intentie om de celtherapieactiviteiten af te bouwen, wat de optimale kapitaalallocatie vertegenwoordigt ter ondersteuning van een sterkere en duurzame toekomst voor GalapagosVerdere ontwikkeling van het leiderschapsteam sluit aan bij de strategische richtingRobuuste balans met €3,05 miljard in geldmiddelen en financiële investeringen per 30 september 2025; verwachte kaspositie eind 2025 tussen €2,975 miljard en €3,025 miljardManagement organis...
The abstracts for presentations at the American Society of Haematology conference (ASH, 6-9 December) became available yesterday during the day (HERE). While we may have to wait until the actual conference for the latest datasets, here in this note are some key takeaways for our coverage including updates from Autolus (new data for Aucatzyl in paediatric ALL, real world data in adult ALL, amongst others), Galapagos (additional CAR-T data in r/r MCL and r/r DLBCL) and MaaT (longer follow up from ...
Galapagos to Present New Data from Cell Therapy Program at ASH 2025 Oral presentation of GLPG5101 data from the ATALANTA-1 study in patients with high-risk relapsed/refractory mantle cell lymphoma Two abstracts featuring new Phase 2 data highlight the potential of CAR-T cell therapy candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma Results demonstrate high rates of complete and durable responses along with low rates of high-grade toxicities using GLPG5101 manufactured on innovative median seven-day vein-to-vein time platform, potentially enabling broader access to cell the...
Galapagos zal nieuwe gegevens presenteren over celtherapieprogramma tijdens ASH 2025 Mondelinge presentatie van GLPG5101-gegevens uit de ATALANTA-1 studie bij patiënten met hoog-risico recidief/refractair mantelcellymfoom Twee abstracts met nieuwe fase 2-gegevens benadrukken het potentieel van CAR-T-celtherapie kandidaat GLPG5101 in recidief/refractaire non-hodgkin lymfoom Resultaten tonen hoge percentages van volledige en duurzame responsen, gecombineerd met lage percentages van ernstige toxiciteiten met GLPG5101, geproduceerd via een innovatief platform met een mediane vein-to-vein tijd...
Aegon announces changes to its Board of Directors Schiphol, November 3, 2025 - Aegon announces today that David Herzog, who was appointed as a member of the Board of Directors (BoD) at Aegon’s 2025 Annual General Meeting of shareholders (AGM), will succeed William Connelly as Chairman of the BoD as of November 13, 2025. In line with previous announcements, Mr Connelly will retire as Chairman and member of the BoD on the same date. Aegon also announces today that it will propose to its 2026 AGM to appoint Leni Boeren as a new member of its BoD. Mrs Boeren has extensive experience in both t...
Fagron’s share buy-back program: Weekly update Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 31 October 2025 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 27 October 2025 through 31 October 2025, Fagron purchased 46,000 of its owns shares at an average price of €20.5831 per share corresponding to a total amount of €946,821.80. These purchases are part of the share buy-back program of up to 200,000 Fagron shares to fulfill Fagron’s obligations under its long-term incentive scheme, which was announced on 9 October 2025. The total numbe...
Voortgang aandeleninkoopprogramma Fagron Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 31 oktober 2025 – 18u CET Voortgang aandeleninkoopprogramma Fagron In de periode van 27 oktober 2025 tot en met 31 oktober 2025 heeft Fagron 46.000 eigen aandelen ingekocht voor een gemiddelde prijs van € 20.5831 per aandeel wat overeenkomt met een totaalbedrag van € 946.821,80. Deze aankopen zijn gedaan als onderdeel van het aandeleninkoopprogramma van maximaal 200.000 Fagron aandelen ter afdekking van Fagron’s verplichtingen uit hoofde van haar langetermijn variabele belonings...
Galapagos kondigt wijzigingen aan in de Raad van Bestuur om de strategische focus op business development te versnellen Nieuwe bestuurders brengen sterke financiële leiderschapservaring, expertise in kapitaalallocatie en business development naar de Raad van Bestuur Mechelen, België; 30 oktober 2025, 21:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) kondigde vandaag verschillende wijzigingen aan in haar Raad van Bestuur, als onderdeel van haar voortdurende inzet voor goed bestuur op de lange termijn en strategische continuïteit. Deze wijzigingen versterken de afstemming van de samenstellin...
Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board Mechelen, Belgium; October 30, 2025, 21:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced several changes to its Board of Directors as part of its ongoing commitment to long-term governance and strategic continuity. These changes strengthen the alignment of the Board’s composition with the Company’s strategic direction and support its focus on transformational busine...
AB InBev: The interim is back. Arcadis: Slow return to organic growth, FCF disappoints. Ayvens: Keeping its promise. dsm-firmenich: Waiting for Godot. D'Ieteren: Boyd prelim 3Q25, $1.3bn M&A deal, NYSE listing, $780m capital increase. Flow Traders: Down but not out. Ontex: FY25F guidance confirmed despite a modestly softer 3Q25. Recticel: Weak 3Q25 but comforting outlook. Shell plc: Solid story with cash continuing to come in strongly. TKH Group: Preview - subsea remains in foc...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.